RESEARCH HIGHLIGHT 08 May 2026 People with a deadly form of pancreatic cancer survive longer on a drug that blocks the activity of a family of mutant proteins. The drug daraxonrasib shrank or halted the growth of pancreatic tumours (yellow; artist’s illustration) in many of the participants in a small clinical trial. Credit: 3Dmedisphere/Science Photo Library A groundbreaking cancer drug has shown promise against deadly, hard-to-treat pancreatic tumours in a small clinical trial 1 . Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue Rent or buy this article Prices vary by article type from $1.95 to $39.95 Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support…